A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary) ; Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Planned End Date changed from 1 Nov 2018 to 1 Apr 2019.
- 12 Nov 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.